Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues
by
Myrick H, Malcolm R, Taylor B, LaRowe S.
Department of Psychiatry and Behavioral Sciences,
Medical University of South Carolina,
Charleston, South Carolina 29425, USA.
myrickh@musc.edu
Ann Clin Psychiatry. 2004 Apr-Jun;16(2):101-9.

ABSTRACT

Modafinil is an agent that is frequently used in the treatment of narcolepsy. More recently it has been used in the treatment of a variety of psychiatric, neurological, and medical illnesses. Due to its ability to improve wakefulness, modafinil has been viewed as a stimulant. Based on the potential for modafinil to become widely used in a variety of syndromes and settings, evidence from preclinical in vitro and in vivo studies, human laboratory studies, and post-marketing experiences examining the potential abuse liability of modafinil were reviewed. Initial evidence suggests that modafinil has limited potential for large-scale abuse.

Narcolepsy
Modafinil: review
Modafinil: structure
Modafinil and serotonin
Tranylcypromine (Parnate)
Modafinil and the marmoset
Excessive daytime sleepiness
Modafinil as an antidepressant
Modafinil versus amphetamine
Modafinil versus methylphenidate
Modafinil, amphetamine and sleep
Fatigue, sleepiness in major depression

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family